Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Zacks Investment Research

23 Jun 2026, 16:46 UTC · 1h ago

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Merck's late-stage Study 2 for tulisokibart met its primary endpoint of clinical remission at week 12 and key secondary endpoints in patients with ulcerative colitis. — Positive phase 3 results for a late-stage asset increase the likelihood of regulatory approval and future revenue growth.
+0.60
2
Merck is utilizing tulisokibart to diversify its revenue stream ahead of the 2028 patent expiration for Keytruda, which currently generates approximately 50% of total company revenues. — Reducing dependency on a single blockbuster drug mitigates long-term systemic risk for the company's valuation.
+0.40
3
Merck has not yet disclosed the detailed efficacy data supporting the positive outcomes of Study 2. — Lack of granular data prevents investors from fully assessing the drug's competitive advantage or strength of effect.
-0.20

Which stocks this story touches

6 related stories

PRNewsWire
2h ago
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
- biotech
- clinical trials
- healthcare
Read

Merck's Anti-TL1A Antibody… — MRK +0.80 | NewsImpactScreener

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

What matters in this story

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

What matters in this story

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout

Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?

Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

What matters in this story

Next reads from the same story arc

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

What matters in this story

Next reads from the same story arc

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout

Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?

Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying